ImmuPharma (AIM:IMM, FRA:25I) says it's on track to deliver a licensing deal for its lead asset P140 this year. The company has also fast-tracked Kapiglucagon, a next-gen diabetes treatment, backed by funding from Lanstead Capital. Ilika (AIM:IKA, OTCQX:ILIKF, FRA:I8A) has had its Goliath solid-state batteries tested under battlefield conditions — including live-fire testing. The results demonstrated the inherent safety advantages of Ilika’s solid-state battery technology compared to traditional lithium-i ...